Last reviewed · How we verify
SHR3680 tablets
At a glance
| Generic name | SHR3680 tablets |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (PHASE2)
- A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC (PHASE2)
- A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects (PHASE1)
- Relative Bioavailability Study of SHR3680 (PHASE1)
- A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer (PHASE3)
- A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC (PHASE1, PHASE2)
- A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR3680 tablets CI brief — competitive landscape report
- SHR3680 tablets updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI